» Articles » PMID: 23605066

Dietary Capsaicin Prevents Nonalcoholic Fatty Liver Disease Through Transient Receptor Potential Vanilloid 1-mediated Peroxisome Proliferator-activated Receptor δ Activation

Overview
Journal Pflugers Arch
Specialty Physiology
Date 2013 Apr 23
PMID 23605066
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic lipid deposition and coincides often with cardiometabolic diseases. Several dietary factors attenuate NAFLD. Here, we report beneficial effects of chronic dietary capsaicin intake on NAFLD which is mediated by the transient receptor potential vanilloid 1 (TRPV1) activation. The results showed that TRPV1 activation by capsaicin reduced free fatty acids (FFAs) induced the intracellular lipid droplets in HepG2 cells and prevented fatty liver in vivo. Chronic dietary capsaicin promoted lipolysis by increasing hepatic phosphorylated hormone-sensitive lipase (phospho-HSL), carnitine palmitoyltransferase 1 (CPT1), and peroxisome proliferator-activated receptor δ (PPARδ) in wild-type (WT) mice. This effect was absent in TRPV1(-/-) mice. Dietary capsaicin did not affect lipogenesis, as indicated by the detection of hepatic fatty acid synthase (FAS), sterol regulatory element-binding protein-1 (SREBP-1), PPARα, and liver X receptor (LXR) in mice. Importantly, TRPV1 causes PPARδ activation which significantly increased the expression of autophagy-related proteins, such as light chain 3 (LC3)II, Beclin1, Atg5, and Atg7 in HepG2 cells. In the in vivo study, TRPV1 activation by dietary capsaicin enhanced hepatic PPARδ and autophagy-related proteins and reduced hepatic enzymes and inflammatory factor in WT but not TRPV1(-/-) mice. TRPV1 activation by dietary capsaicin prevents NAFLD through PPARδ-dependent autophagy enhancement in mice. Dietary capsaicin may represent a beneficial intervention in populations at high risk for NAFLD.

Citing Articles

Targeting lipid droplets and lipid droplet-associated proteins: a new perspective on natural compounds against metabolic diseases.

Jiang X, Wang H, Nie K, Gao Y, Chen S, Tang Y Chin Med. 2024; 19(1):120.

PMID: 39232826 PMC: 11373146. DOI: 10.1186/s13020-024-00988-w.


Effects of dietary capsaicin supplementation on growth performance, blood profile and carcass and meat quality of finishing pigs.

Namted S, Poungpong K, Bunchasak C Anim Biosci. 2024; 37(11):1953-1961.

PMID: 38754848 PMC: 11541037. DOI: 10.5713/ab.23.0541.


Regulation Mechanism and Potential Value of Active Substances in Spices in Alcohol-Liver-Intestine Axis Health.

Huang J, Huang T, Li J Int J Mol Sci. 2024; 25(7).

PMID: 38612538 PMC: 11011869. DOI: 10.3390/ijms25073728.


Role of TRP Channels in Metabolism-Related Diseases.

Wu F, Bu S, Wang H Int J Mol Sci. 2024; 25(2).

PMID: 38255767 PMC: 10815096. DOI: 10.3390/ijms25020692.


Pharmacological activity of capsaicin: Mechanisms and controversies (Review).

Zhang W, Zhang Y, Fan J, Feng Z, Song X Mol Med Rep. 2024; 29(3).

PMID: 38240083 PMC: 10828990. DOI: 10.3892/mmr.2024.13162.


References
1.
Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

2.
Malavazos A, Gobbo G, Zelaschi R, Cereda E . Lifestyle intervention and fatty liver disease: the importance of both disrupting inflammation and reducing visceral fat. Hepatology. 2009; 51(3):1091-2. DOI: 10.1002/hep.23409. View

3.
Holzer P . Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol Ther. 2011; 131(1):142-70. PMC: 3107431. DOI: 10.1016/j.pharmthera.2011.03.006. View

4.
Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K . Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol. 2006; 536(1-2):182-91. DOI: 10.1016/j.ejphar.2006.02.028. View

5.
Nilius B, Owsianik G, Voets T, Peters J . Transient receptor potential cation channels in disease. Physiol Rev. 2007; 87(1):165-217. DOI: 10.1152/physrev.00021.2006. View